Comparison of urinary markers for bone resorption in multiple myeloma.
Multiple myeloma causes extensive bone remodeling. Classical biochemical markers such as urinary calcium have poor sensitivity for detecting multiple myeloma bone remodeling. New biochemicals have been developed including a carboxyterminal telopeptide of collagen I (CTX). We used an immunoenzymatic assay to determine urinary CTX in 60 patients with multiple myeloma. This marker was evaluated with regard to total pyridinolines, urinary calcium, radiological features, pain and response to treatment with bisphosphonates. In patients with bone involvement, CTX concentrations were significantly higher (+230%) than those of deoxypyridinoline (DPD) (+175%) and pyridinolines (PYD) (+130%). In all patients we have found a close correlation between CTX and DPD but not between CTX and PYD. Compared to radiological features, CTX was more sensitive (97%) and specific (96%) than DPD. After treatment by bisphosphonates, the fall in CTX concentrations was paralleled to urinary calcium and more marked than pyridinolines. Although our results need to be confirmed, CTX appears to be a potential marker to explore bone involvement in multiple myeloma.
Houzé
P
P
Laboratoire de Biochimie, Hôpital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France. biochemie-u@chu-stlouis.fr
Bellik
B
B
Brouet
J C
JC
Bouro
F
F
Bousquet
B
B
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000652:urine*; D001862:Bone Resorption; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000503:physiopathology* / Q000652:urine
D015415:Biomarkers